|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4889818A
(en)
|
1986-08-22 |
1989-12-26 |
Cetus Corporation |
Purified thermostable enzyme
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
EP1983057A3
(en)
|
1995-09-08 |
2009-01-07 |
Genzyme Corporation |
Improved AAV vectors for gene therapy
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
US6635472B1
(en)
|
1997-08-15 |
2003-10-21 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
|
CA2304168A1
(en)
|
1997-09-19 |
1999-04-01 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
EP1058500A4
(en)
|
1998-02-27 |
2002-05-08 |
Gen Hospital Corp |
The helios gene
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
ES2340230T3
(es)
|
1998-11-10 |
2010-05-31 |
University Of North Carolina At Chapel Hill |
Vectores viricos y sus procedimientos de preparacion y administracion.
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
US6168991B1
(en)
|
1999-06-25 |
2001-01-02 |
Lucent Technologies Inc. |
DRAM capacitor including Cu plug and Ta barrier and method of forming
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US6723316B2
(en)
|
1999-12-22 |
2004-04-20 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth
|
|
DE60115600T2
(de)
|
2000-01-21 |
2006-07-20 |
Biovex Ltd. |
Virusstämme für die onkolytische behandlung von krebs
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
EP1385466B1
(en)
|
2001-05-11 |
2011-03-09 |
Wellstat Biologics Corporation |
Oncolytic virus therapy
|
|
US20030044386A1
(en)
|
2001-07-11 |
2003-03-06 |
Barber Glen N. |
Recombinant VSV for the treatment of tumor cells
|
|
AU2003258060B2
(en)
|
2002-03-27 |
2007-07-12 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
NZ537255A
(en)
|
2002-06-21 |
2009-04-30 |
Wellstat Biologics Corp |
Administration of therapeutic viruses
|
|
JP2005537802A
(ja)
|
2002-09-09 |
2005-12-15 |
ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション |
ラブドウイルスの組み換え型変異体及びその使用方法
|
|
DE602004018284D1
(de)
|
2003-03-27 |
2009-01-22 |
Ottawa Health Research Inst |
Mutante vesicular stomatitis viren und deren verwendungen
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
EP1644492B1
(en)
|
2003-06-18 |
2009-01-07 |
Genelux Corporation |
Modified recombinant vaccinia viruses, uses thereof
|
|
CN1856576B
(zh)
|
2003-09-30 |
2011-05-04 |
宾夕法尼亚州立大学托管会 |
腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
WO2005049846A2
(en)
|
2003-11-17 |
2005-06-02 |
Crusade Laboratories Limited |
Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
DE602005016683D1
(de)
|
2004-07-10 |
2009-10-29 |
Fox Chase Cancer Ct |
Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
|
|
WO2006060314A2
(en)
|
2004-12-01 |
2006-06-08 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
AU2006252406B2
(en)
|
2005-06-01 |
2012-05-17 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
|
CN101495126B
(zh)
|
2005-06-23 |
2016-01-06 |
休斯顿大学 |
Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
EP2426142A3
(en)
|
2006-10-16 |
2012-06-13 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
|
EP2114420B1
(en)
|
2007-02-16 |
2016-01-27 |
Virttu Biologics Limited |
Herpes simplex viruses and methods of viral replication
|
|
WO2008133938A2
(en)
|
2007-04-26 |
2008-11-06 |
Sangamo Biosciences, Inc. |
Targeted integration into the ppp1r12c locus
|
|
JP5213075B2
(ja)
|
2007-06-15 |
2013-06-19 |
ジェネラックス・コーポレイション |
腫瘍の画像化および／または処置のための微生物
|
|
WO2009011924A1
(en)
|
2007-07-18 |
2009-01-22 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
JP5282040B2
(ja)
|
2007-09-28 |
2013-09-04 |
オリンパス株式会社 |
Ｆｃ受容体遺伝子導入ＮＫ細胞を用いた抗体依存性細胞傷害のアッセイ方法
|
|
US20090136917A1
(en)
|
2007-10-25 |
2009-05-28 |
Szalay Aladar A |
Systems and methods for viral therapy
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
WO2009139921A2
(en)
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
EP2307033A4
(en)
|
2008-05-29 |
2012-06-13 |
Gen Hospital Corp |
USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
|
|
KR101133185B1
(ko)
|
2008-07-29 |
2012-04-06 |
서울대학교병원 |
자연살해세포의 증식방법
|
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
US8877182B2
(en)
*
|
2009-03-26 |
2014-11-04 |
Cellprotect Nordic Pharmaceuticals Ab |
Expansion of NK cells
|
|
WO2012061814A1
(en)
|
2010-11-05 |
2012-05-10 |
Transgenomic, Inc. |
Pcr primers and methods for rapid and specific genotyping
|
|
US10066207B2
(en)
|
2012-04-18 |
2018-09-04 |
Board Of Trustees Of Michigan State University |
Natural killer cells with enhanced immune response
|
|
EP2893003B1
(en)
*
|
2012-09-04 |
2021-03-31 |
Inven2 AS |
Selective and controlled expansion of educated nk cells
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
US9902973B2
(en)
|
2013-04-11 |
2018-02-27 |
Caribou Biosciences, Inc. |
Methods of modifying a target nucleic acid with an argonaute
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
US10813952B2
(en)
|
2014-11-14 |
2020-10-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
|
|
US20170137784A1
(en)
|
2015-03-23 |
2017-05-18 |
Cellex Corporation |
NK Cell Culture Container And NK Cell Culture Method
|
|
CN107708741A
(zh)
|
2015-06-12 |
2018-02-16 |
免疫医疗公司 |
用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
|
|
EP4043556B1
(en)
|
2015-06-30 |
2024-02-07 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
ES2970269T3
(es)
|
2015-07-29 |
2024-05-27 |
Onk Therapeutics Ltd |
Linfocitos citolíticos naturales modificados y líneas de linfocitos citolíticos naturales que tienen citotoxicidad aumentada
|
|
WO2017048809A1
(en)
|
2015-09-14 |
2017-03-23 |
Regents Of The University Of Minnesota |
Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
|
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
JP6928604B2
(ja)
|
2015-11-04 |
2021-09-01 |
フェイト セラピューティクス，インコーポレイテッド |
万能性細胞のゲノム改変
|
|
EP3405568A4
(en)
|
2016-01-20 |
2019-12-04 |
Fate Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
|
|
CA3010236A1
(en)
|
2016-01-20 |
2017-07-27 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
CN109844099B
(zh)
*
|
2016-07-25 |
2024-01-02 |
美国政府(由卫生和人类服务部的部长所代表) |
产生经修饰的自然杀伤细胞的方法及使用方法
|
|
CN110546265A
(zh)
|
2017-02-09 |
2019-12-06 |
因达普塔治疗公司 |
工程化自然杀伤(nk)细胞及其组合物和方法
|
|
EP3539552A1
(en)
|
2018-03-16 |
2019-09-18 |
Deutsches Rheuma-Forschungszentrum Berlin |
Activation and expansion of nkg2c+ nk cells
|
|
JP6543375B1
(ja)
|
2018-03-27 |
2019-07-10 |
株式会社ガイアバイオメディシン |
ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用
|
|
EP4474391A3
(en)
|
2018-05-14 |
2025-02-26 |
Indapta Therapeutics, Inc. |
Subsets of human natural killer cells with enhanced antibody-directed immune responses
|
|
US12410402B2
(en)
|
2018-11-21 |
2025-09-09 |
Indapta Therapeutics, Inc. |
Methods for expansion of natural killer (NK) cell subset and related compositions and methods
|